[go: up one dir, main page]

DE60002142D1 - 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazol- und 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazol- Derivate, ihr Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, diese enthaltend - Google Patents

12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazol- und 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazol- Derivate, ihr Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, diese enthaltend

Info

Publication number
DE60002142D1
DE60002142D1 DE60002142T DE60002142T DE60002142D1 DE 60002142 D1 DE60002142 D1 DE 60002142D1 DE 60002142 T DE60002142 T DE 60002142T DE 60002142 T DE60002142 T DE 60002142T DE 60002142 D1 DE60002142 D1 DE 60002142D1
Authority
DE
Germany
Prior art keywords
indolo
carbazole
alkyl
nrarb
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60002142T
Other languages
English (en)
Other versions
DE60002142T2 (de
Inventor
Michelle Prudhomme
Pascale Moreau
Fabrice Anizon
Christelle Marminon
Ghanem Atassi
Alain Pierre
Bruno Pfeiffer
Pierre Renard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Servier SAS
Original Assignee
Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Servier SAS filed Critical Laboratoires Servier SAS
Application granted granted Critical
Publication of DE60002142D1 publication Critical patent/DE60002142D1/de
Publication of DE60002142T2 publication Critical patent/DE60002142T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
DE60002142T 1999-11-17 2000-11-09 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazol- und 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazol- Derivate, ihr Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, diese enthaltend Expired - Fee Related DE60002142T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9914433A FR2801054B1 (fr) 1999-11-17 1999-11-17 Nouveaux derives de 12,13-(pyranosyl)-indolo[2,3-a]pyrrolo [3,4-c]carbazole et 12,13-(pyranosyl)-furo[3,4-c]indolo [2,3-a]carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR9914433 1999-11-17

Publications (2)

Publication Number Publication Date
DE60002142D1 true DE60002142D1 (de) 2003-05-22
DE60002142T2 DE60002142T2 (de) 2004-03-18

Family

ID=9552202

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60002142T Expired - Fee Related DE60002142T2 (de) 1999-11-17 2000-11-09 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazol- und 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazol- Derivate, ihr Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, diese enthaltend

Country Status (23)

Country Link
US (1) US6569858B2 (de)
EP (1) EP1101770B1 (de)
JP (1) JP3602050B2 (de)
KR (1) KR100453980B1 (de)
CN (1) CN1152040C (de)
AT (1) ATE237625T1 (de)
AU (1) AU771584B2 (de)
BR (1) BR0005426A (de)
CA (1) CA2325779C (de)
DE (1) DE60002142T2 (de)
DK (1) DK1101770T3 (de)
EA (1) EA004737B1 (de)
ES (1) ES2197061T3 (de)
FR (1) FR2801054B1 (de)
HK (1) HK1036991A1 (de)
HU (1) HUP0004574A3 (de)
MX (1) MXPA00010899A (de)
NO (1) NO20005796L (de)
NZ (1) NZ508231A (de)
PL (1) PL343879A1 (de)
PT (1) PT1101770E (de)
SI (1) SI1101770T1 (de)
ZA (1) ZA200006729B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677450B2 (en) * 2000-10-06 2004-01-13 Bristol-Myers Squibb Company Topoisomerase inhibitors
US6610727B2 (en) 2000-10-06 2003-08-26 Bristol-Myers Squibb Company Anhydro sugar derivatives of indolocarbazoles
US6653290B2 (en) 2000-10-06 2003-11-25 Bristol-Myers Squibb Company Tumor proliferation inhibitors
MXPA03008589A (es) 2001-03-22 2003-12-08 Bristol Myers Squibb Co Derivados de azucar citotoxicos selectivos de topoisomerasa i de indolopirrolocarbazoles.
FR2826653B1 (fr) * 2001-06-29 2005-10-14 Servier Lab Nouveaux derives de pyrido-pyrido-pyrrolo[3,2-g]pyrrolo [3,4-e]-indole et pyrido-pyrrolo[2,3-a]pyrrolo[3,4-c] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2831169B1 (fr) * 2001-10-22 2003-12-12 Servier Lab Nouveaux derives d'hydroxyalkyle indolocarbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ES2326459B1 (es) 2008-04-08 2010-05-28 Universidad De Oviedo Indolocarbazoles glicosilados, su procedimiento de obtencion y sus usos.
CN104031052B (zh) * 2014-05-20 2016-06-08 中国科学院南海海洋研究所 抗生素Indimicins A–E及其制备方法和在制备抗肿瘤药物中的应用
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
AU2019309894A1 (en) 2018-07-27 2021-01-28 Biotheryx, Inc. Bifunctional compounds as CDK modulators
RU2726801C1 (ru) * 2019-10-16 2020-07-15 Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр онкологии имени Н.Н. Блохина" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ онкологии им. Н.Н. Блохина" Минздрава России) Средство для терапии опухолей
WO2021222150A2 (en) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015578A (en) * 1989-03-23 1991-05-14 Bristol-Myers Squibb Company BMY-41950 antitumor antibiotic
JPH05140168A (ja) * 1991-11-13 1993-06-08 Asahi Chem Ind Co Ltd インドロカルバゾール誘導体及び該化合物を有効成分とする抗腫瘍剤
NZ245203A (en) * 1991-11-29 1997-07-27 Banyu Pharma Co Ltd 5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione derivatives substituted in position-13 by a pentose or hexose group; corresponding indolo-furano(anhydride)intermediates
JPH07112987A (ja) * 1993-10-14 1995-05-02 Asahi Chem Ind Co Ltd スタウロスポリン糖部分変換誘導体
CO4940430A1 (es) * 1997-07-07 2000-07-24 Novartis Ag Compuestos policiclicos que contienen estaurosporina hidrogenada con propiedades farmacologicas convenientes y un efecto inhibidor sobre el crecimiento de las celulas tumorales

Also Published As

Publication number Publication date
HUP0004574A2 (hu) 2001-10-28
KR100453980B1 (ko) 2004-10-20
US6569858B2 (en) 2003-05-27
EA200001078A1 (ru) 2001-06-25
KR20010051775A (ko) 2001-06-25
JP2001139578A (ja) 2001-05-22
MXPA00010899A (es) 2002-05-23
AU771584B2 (en) 2004-03-25
DE60002142T2 (de) 2004-03-18
ZA200006729B (en) 2001-06-05
HUP0004574A3 (en) 2001-12-28
PL343879A1 (en) 2001-05-21
NO20005796D0 (no) 2000-11-16
PT1101770E (pt) 2003-07-31
NZ508231A (en) 2001-09-28
EP1101770B1 (de) 2003-04-16
ES2197061T3 (es) 2004-01-01
BR0005426A (pt) 2001-07-03
HK1036991A1 (en) 2002-01-25
NO20005796L (no) 2001-05-18
DK1101770T3 (da) 2003-08-04
EA004737B1 (ru) 2004-08-26
CN1152040C (zh) 2004-06-02
CN1303859A (zh) 2001-07-18
US20020055510A1 (en) 2002-05-09
FR2801054B1 (fr) 2003-06-13
FR2801054A1 (fr) 2001-05-18
SI1101770T1 (en) 2003-08-31
ATE237625T1 (de) 2003-05-15
CA2325779C (fr) 2006-07-11
EP1101770A1 (de) 2001-05-23
AU7168100A (en) 2002-01-03
JP3602050B2 (ja) 2004-12-15
HU0004574D0 (de) 2001-02-28
CA2325779A1 (fr) 2001-05-17

Similar Documents

Publication Publication Date Title
DE60002142D1 (de) 12,13-(pyranosyl)-indolo(2,3-a)pyrrolo(3,4-c)carbazol- und 12,13-(pyranosyl)-furo(3,4-c)indolo(2,3-a)carbazol- Derivate, ihr Verfahren zur Herstellung und pharmazeutische Zusammensetzungen, diese enthaltend
FR2654104B1 (fr) Nouveaux derives du 1,2-benzisoxazole, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent.
ATE226208T1 (de) 4-oxo-4,7-dihydro-thieno(2,3-b)pyridin-5- carboxamide als antivirale mittel
FR2619111B1 (fr) Derives de (piperidinyl-4)methyl-2 tetrahydro-1,2,3,4 9h-pyrido (3,4-b) indole, leur preparation et leur application en therapeutique
RU96111027A (ru) Трициклические 5,6-дигидро-9h-пиразоло [3,4-c]-1,2,4-триазоло [4,3-a]пиридины
TNSN92049A1 (fr) DERIVES D'IMIDAZO (1,2-a) (PYRROLO, THIENO OU FURANO) (3,2-d) AZEPINE, COMPOSITIONS RENFERMANT CES DERIVES ET METHODES POUR LEUR UTILISATION
FI910126L (fi) Menetelmä farmaseuttisesti käyttökelpoisen 4-(5,6,7,8-tetrahydroimidatso/1,5-a/pyridin-5-yyli)-bentsonitriilin hydrokloridin valmistamiseksi kiteisessä hemihydraattimuodossa
KR950700293A (ko) 세로토닌작동성의 에르골린 유도체(Serotoninergic ergoline derivatives)
ATE239023T1 (de) Antiallergische imidazo(1,2-a)thieno(2,3- d)azepinderivate
DE60000125D1 (de) 7-Oxo-2,3,7,14-tetrahydro-1H-benzo[b]pyrano[3,2-h]acridincarboxylatderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
KR950032205A (ko) 5,6-디 히드로-4H-티에노 [3,4-c] 피롤유도체, 그것의 제조방법 및 치료에의 이용
BG108423A (en) Dihydroimidazo[5,1-a]beta-carboline derivatives, method for preparing same and use thereof as medicine
DE69103934D1 (de) 4H-Pyrrolo[1,2-a]thieno[3,2-f][1,4]diazepinderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen.
FR2767132B1 (fr) Nouveaux composes de bis pyrido [4,3-b] carbazole, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
NO922812L (no) Naftyridin- og kinolizinderivater og farmasoeytiske preparater inneholdende disse
ATE113046T1 (de) Triazolo(4,5-c>pyridinderivate mit krampflindernder wirkung.
RU2000106033A (ru) Производные 3-замещенного 3,4,5,7-тетрагидропирроло[3',4':4,5]тиено[2,3-d]-пиримидина

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee